Oncologie nieuws
- ImmunityBio gets US FDA nod for its Anktiva to treat patient with BCG?unresponsive non?muscle invasive bladder cancer
- FDA Approves Alectinib as Adjuvant Treatment for ALK-positive Non-Small Cell Lung Cancer
- US FDA accepts GSK's sBLA for Jemperli plus chemotherapy to expand treatment to all adult patients with primary advanced or recurrent endometrial cancer
- Expression of Concern: Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling
- Erratum: Pathologic Exploration of the Axillary Soft Tissue Microenvironment and Its Impact on Axillary Management and Breast Cancer Outcomes
- Racial/Ethnic Disparities in Pathologic Complete Response and Overall Survival in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy
- Brusatol hinders the progression of bladder cancer by Chac1/Nrf2/SLC7A11 pathway
- PLAU promotes cell proliferation and migration of head and neck cancer via STAT3 signaling pathway
- Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom
- GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
- Applicability of mono dysplasia score on the new Sysmex XR analyzer range to predict diagnosis of chronic myelomonocytic leukaemia
- Thrombosis risk prediction in lymphoma patients: A multi?institutional, retrospective model development and validation study
- Adjuvant Pembrolizumab Improves Overall Survival Among Patients with Clear-Cell Renal Cell Carcinoma Who Are At Increased Risk for Disease Recurrence After Nephrectomy
- Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
- Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer